Glenmark Pharmaceuticals Limited
http://www.glenmarkpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Glenmark Pharmaceuticals Limited
Hypertension To Mental Health Drugs: Indian Firms Supplied Bulk Of Rx Volume In US
Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Asia Deal Watch: Takeda To Team Up With Protagonist On Treatment For Polycythemia Vera
Plus alliances involving Formosa/Cristalia, Renalys/Travere, Astellas/Vivtex, Zydus/Synthon, AFT/Hyloris and Astellas/Mass General Brigham hospital.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Integrace
- Integrace Private Limited
- Ichnos Sciences
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice